Based on these observations, we selected two oncogene-driven non-small cell lung cancer (NSCLC) cell lines that are resistant to EGFR inhibitors and tested whether treatment with ATM inhibitor may enhance sensitivity to EGFR inhibitors in those cells investigating the underlying molecular mechanisms. The gene discussed is ATM; the disease is non-small cell lung carcinoma.